As AbbeVie faces the off-patent realities of its blockbuster Humira, the company is gearing up for the launch of Skyrizi (risankizumab), its interleukin-23 inhibitor psoriasis drug. The drug has gained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), and if US FDA grants its approval, the company will launch Skyrizi almost simultaneously in Europe and the US. Discover more here about the progress of a Skyrizi launch and what it means for AbbeVie.